Sartorius AG

EANS-Adhoc: Sartorius AG
Both divisions with substantial gains in order intake and sales revenue | Group profitability significantly increased | Strong operating cash flow | Considerable growth and further increase in profitability expected for 2011

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.

Preliminary Figures for Fiscal 2010


In 2010, order intake grew 10.7% (currency-adj.: +7.5%) to EUR681.1 million from EUR615.1 million a year ago; Group sales revenue rose 9.5% (+6.4%) to EUR659.3 million from EUR602.1 million a year earlier. Despite the H1N1 base effect in 2009, order volume for the Biotechnology Division climbed 8.1% (currency-adj. +5.0%) to EUR442.3 million (prev. year: EUR409.2 mn.); its sales revenue grew 8.0% (+5.1%) to EUR432.6 million from EUR400.4 million a year ago. The Mechatronics Division strongly recovered from the recession-induced decline a year earlier and posted substantial gains both in order intake, up 16.0% (+12.4%), to EUR238.8 million (prev. year EUR205.9 mn.), and in sales revenue, up 12.4% (+8.9%), to EUR226.7 million (prev. year EUR201.7 mn.).

Operating earnings — consolidated earnings before interest, taxes and amortization and adjusted for extraordinary items of -EUR6.3 million (2009: -EUR30.0 mn.) — soared EUR24.6 million, or 40.4%, to EUR85.5 million. The corresponding margin climbed from 10.1% to 13.0%. The Biotechnology Division contributed EUR70.2 million, up from EUR60.2 million in 2009, and the Mechatronics Division EUR15.3 million, up from EUR0.7 million in 2009, to operating earnings. Their respective margins improved from 15.0% to 16.2% (Biotechnology) and from 0.4% to 6.8% (Mechatronics).

Underlying consolidated net profit after minority interest and excluding amortization rose significantly from EUR20.8 million to EUR39.0 million; the respective earnings per share surged from EUR1.22 to EUR2.29. The unadjusted consolidated net profit after minority interest totals EUR31.0, up from -EUR7.3 million a year ago. Along with positive business development and the resulting strong operating cash flow, the ratio of net debt to underlying EBITDA improved from 2.6 to 1.8.

For fiscal 2011, management expects sales revenue to grow between 6% and 8% in constant currencies for both divisions and, therefore, also at Group level. The operating earnings margin is projected to increase to around 14% (Biotechnology: around 17%; Mechatronics: around 8%) in constant currencies. Moreover, management anticipates a significantly positive operating cash flow.

The numbers given above are subject to final review by the auditors. The final figures will be released at the annual press conference on March 14, 2011.

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, will discuss the results with analysts and investors on Wednesday, February 9, 2011, at 4:00 p.m. Central European Time (CET) in a webcast teleconference. You may dial into the teleconference starting at 3:45 p.m. CET at the following numbers: Germany: +49 (0)69 5007 1305; France: +33 (0)1 70 99 42 98; UK: +44 (0)20 7806 1950; USA: +1 718 354 1385. The dial-in code is as follows: 9225134. The webcast and presen-tation can be viewed at

end of announcement                               euro adhoc

Further inquiry note:

Andreas Wiederhold
Team Leader Treasury & Investor Relations
Telefon: +49 (0)551 308-1668

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade

Original-Content von: Sartorius AG, übermittelt durch news aktuell

Weitere Meldungen: Sartorius AG

Das könnte Sie auch interessieren: